Tempest Therapeutics, Inc. (NASDAQ:TPST) · earnings preview
Quarter
Q3
EPS estimate to actual
-$0.32
At a glance
Key takeaways
01Tempest Therapeutics will report Q3 2026 earnings on November 04, 2026 after market close with analysts expecting a loss of $0.32 per share.
02The stock trades at $0.47 with a market capitalization of $14.1 million, indicating a very small-cap healthcare company.
03Recent quarterly results show expanding losses, with Q1 2026 missing estimates by 80% and Q2 missing by 13.3%, suggesting deteriorating financial performance.
04Investors should evaluate revenue trends, margin performance, and forward guidance beyond the headline EPS figure to assess the company's trajectory.
Earnings Results
Tempest Therapeutics, Inc. (NASDAQ:TPST) is scheduled to report its Q3 earnings results on November 04, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.32, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $0.47 with a market capitalization of $14.1M.
Ahead of Tempest Therapeutics, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Tempest Therapeutics, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.